391 related articles for article (PubMed ID: 19761259)
1. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259
[TBL] [Abstract][Full Text] [Related]
2. Correctors promote folding of the CFTR in the endoplasmic reticulum.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2008 Jul; 413(1):29-36. PubMed ID: 18361776
[TBL] [Abstract][Full Text] [Related]
3. The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR.
Du K; Sharma M; Lukacs GL
Nat Struct Mol Biol; 2005 Jan; 12(1):17-25. PubMed ID: 15619635
[TBL] [Abstract][Full Text] [Related]
4. Dynasore inhibits removal of wild-type and DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) from the plasma membrane.
Young A; Gentzsch M; Abban CY; Jia Y; Meneses PI; Bridges RJ; Bradbury NA
Biochem J; 2009 Jul; 421(3):377-85. PubMed ID: 19442237
[TBL] [Abstract][Full Text] [Related]
5. Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry.
Lewis HA; Wang C; Zhao X; Hamuro Y; Conners K; Kearins MC; Lu F; Sauder JM; Molnar KS; Coales SJ; Maloney PC; Guggino WB; Wetmore DR; Weber PC; Hunt JF
J Mol Biol; 2010 Feb; 396(2):406-30. PubMed ID: 19944699
[TBL] [Abstract][Full Text] [Related]
6. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
Wang Y; Loo TW; Bartlett MC; Clarke DM
Mol Pharmacol; 2007 Mar; 71(3):751-8. PubMed ID: 17132688
[TBL] [Abstract][Full Text] [Related]
7. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.
Wang Y; Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(46):33247-33251. PubMed ID: 17911111
[TBL] [Abstract][Full Text] [Related]
8. Domain interdependence in the biosynthetic assembly of CFTR.
Cui L; Aleksandrov L; Chang XB; Hou YX; He L; Hegedus T; Gentzsch M; Aleksandrov A; Balch WE; Riordan JR
J Mol Biol; 2007 Jan; 365(4):981-94. PubMed ID: 17113596
[TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator (CFTR) nucleotide-binding domain 1 (NBD-1) and CFTR truncated within NBD-1 target to the epithelial plasma membrane and increase anion permeability.
Clancy JP; Hong JS; Bebök Z; King SA; Demolombe S; Bedwell DM; Sorscher EJ
Biochemistry; 1998 Oct; 37(43):15222-30. PubMed ID: 9790686
[TBL] [Abstract][Full Text] [Related]
10. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70.
Farinha CM; Nogueira P; Mendes F; Penque D; Amaral MD
Biochem J; 2002 Sep; 366(Pt 3):797-806. PubMed ID: 12069690
[TBL] [Abstract][Full Text] [Related]
11. Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone.
Scott-Ward TS; Amaral MD
FEBS J; 2009 Dec; 276(23):7097-109. PubMed ID: 19878303
[TBL] [Abstract][Full Text] [Related]
12. Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation.
Cormet-Boyaka E; Jablonsky M; Naren AP; Jackson PL; Muccio DD; Kirk KL
Proc Natl Acad Sci U S A; 2004 May; 101(21):8221-6. PubMed ID: 15141088
[TBL] [Abstract][Full Text] [Related]
13. Expression and characterization of the NBD1-R domain region of CFTR: evidence for subunit-subunit interactions.
Neville DC; Rozanas CR; Tulk BM; Townsend RR; Verkman AS
Biochemistry; 1998 Feb; 37(8):2401-9. PubMed ID: 9485388
[TBL] [Abstract][Full Text] [Related]
14. Restoration of domain folding and interdomain assembly by second-site suppressors of the DeltaF508 mutation in CFTR.
He L; Aleksandrov LA; Cui L; Jensen TJ; Nesbitt KL; Riordan JR
FASEB J; 2010 Aug; 24(8):3103-12. PubMed ID: 20233947
[TBL] [Abstract][Full Text] [Related]
15. Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump.
Loo TW; Bartlett MC; Shi L; Clarke DM
Biochem Pharmacol; 2012 Feb; 83(3):345-54. PubMed ID: 22138447
[TBL] [Abstract][Full Text] [Related]
16. Association of domains within the cystic fibrosis transmembrane conductance regulator.
Ostedgaard LS; Rich DP; DeBerg LG; Welsh MJ
Biochemistry; 1997 Feb; 36(6):1287-94. PubMed ID: 9063876
[TBL] [Abstract][Full Text] [Related]
17. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting.
Bruscia E; Sangiuolo F; Sinibaldi P; Goncz KK; Novelli G; Gruenert DC
Gene Ther; 2002 Jun; 9(11):683-5. PubMed ID: 12032687
[TBL] [Abstract][Full Text] [Related]
18. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy.
Hall JD; Wang H; Byrnes LJ; Shanker S; Wang K; Efremov IV; Chong PA; Forman-Kay JD; Aulabaugh AE
Protein Sci; 2016 Feb; 25(2):360-73. PubMed ID: 26444971
[TBL] [Abstract][Full Text] [Related]
19. The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2010 Aug; 49(30):6352-7. PubMed ID: 20590134
[TBL] [Abstract][Full Text] [Related]
20. Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure.
Lewis HA; Zhao X; Wang C; Sauder JM; Rooney I; Noland BW; Lorimer D; Kearins MC; Conners K; Condon B; Maloney PC; Guggino WB; Hunt JF; Emtage S
J Biol Chem; 2005 Jan; 280(2):1346-53. PubMed ID: 15528182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
